Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT3645 in advanced solid tumors
NCT05538572Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of PRT3645 in breast cancer, glioblastoma (GBM), head and neck squamous cell carcinoma (HNSCC) and 4 more, sponsored by Prelude Therapeutics. Primary endpoints: Dose limiting toxicity at 28 days, Safety and Tolerability (AEs, CTCAE) at 2 years and 2 more. Started Dec 2022; status: completed.
02
Drugs
PRT3645
03
Conditions
breast cancerglioblastoma (GBM)head and neck squamous cell carcinoma (HNSCC)malignant mesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05538572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538572.